Chatzellis E, et al. - In patients with advanced neuroendocrine neoplasms (NENs), capecitabine and temozolomide combination (CAPTEM) is correlated with high response rates, so researchers assessed the real-world activity and safety of CAPTEM from three NEN centers. For this investigation, they retrospectively analyzed clinicopathological features and outcomes of patients treated with CAPTEM for bulky or progressive disease (PD). Participants in the study were 79 patients with gastroenteropancreatic and lung/thymic NENs. Even after protracted administration, CAPTEM treatment can be an efficacious and safe for patients with various sites of NENs and Ki67 labeling index, connected with important favorable responses and progression-free survival.